Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias : An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
Lewczuk, Piotr (University Hospital of Białystok)
Riederer, Peter (University Hospital Würzburg)
O'Bryant, Sid E. (University of North Texas Health Science Center)
Verbeek, Marcel M. (Radboud Alzheimer center)
Dubois, Bruno (Salpêtrièrie Hospital)
Visser, Pieter Jelle (Vrije Universiteit Amsterdam)
Jellinger, Kurt A. (Institute of Clinical Neurobiology)
Engelborghs, Sebastiaan (University Hospital Antwerp (Bèlgica))
Ramirez, Alfredo (University of Cologne)
Parnetti, Lucilla (University of Perugia)
Jack Jr, Clifford R. (Mayo Clinic)
Teunissen, Charlotte E. (VU University Medical Center Amsterdam)
Hampel, Harald (heimer (IM2A). Hôpital Pitié-Salpêtrière)
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau)
Jessen, Frank (German Center for Neurodegenerative Disorders (DZNE))
Glodzik, Lidia (NYU Langone Medical Center)
de Leon, Mony J. (NYU Langone Medical Center)
Fagan, Anne M. (Washington University School of Medicine)
Molinuevo, José Luis (Hospital Clínic i Provincial de Barcelona)
Jansen, Willemijn J. (Maastricht University)
Winblad, Bengt (Karolinska Institutet (Estocolm, Suècia))
Shaw, Leslie M. (University of Pennsylvania)
Andreasson, Ulf (The Sahlgrenska Academy at the University of Gothenburg)
Otto, Markus (University of Ulm)
Mollenhauer, Brit (Kassel and University Medical Center Göttingen)
Wiltfang, Jens (University of Aveiro)
Turner, Martin R. (University of Oxford)
Zerr, Inga (German Center for Neurodegenerative Diseases)
Handels, Ron (Karolinska Institutet (Estocolm, Suècia))
Thompson, Alexander G. (University of Oxford)
Johansson, Gunilla (Karolinska Institutet (Estocolm, Suècia))
Ermann, Natalia (Universitätsklinikum Erlangen. and Friedrich-Alexander Universität Erlangen-Nürnberg)
Trojanowski, John Q. (University of Pennsylvania)
Karaca, Ilker (University of Bonn)
Wagner, Holger (University of Bonn)
Oeckl, Patrick (University of Ulm)
van Waalwijk van Doorn, Linda (Radboud Alzheimer center)
Bjerke, Maria (University of Antwerp)
Kapogiannis, Dimitrios (National Institute on Aging/National Institutes of Health (NIA/NIH))
Kuiperij, H.Bea (Radboud Alzheimer center)
Farotti, Lucia (University of Perugia)
Li, Yi (NYU Langone Medical Center)
Gordon, Brian A. (Washington University School of Medicine)
Epelbaum, Stéphane (Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A))
Vos, Stephanie J.B. (Maastricht University)
Klijn, Catharina J.M. (Radboud Alzheimer Center)
Van Nostrand, William E. (Stony Brook University)
Minguillon, Carolina (Fundació Pasqual Maragall)
Schmitz, Matthias (University Medical School)
Gallo, Carla (Universidad Peruana Cayetano Heredia)
Lopez Mato, Andrea (Maimonides University)
Thibaut, Florence (University Hospital Cochin-Site Tarnier 89 rue d'Assas)
Lista, Simone (heimer (IM2A). Hôpital Pitié-Salpêtrière)
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau)
Zetterberg, Henrik (UCL Institute of Neurology (Regne Unit))
Blennow, Kaj (Sahlgrenska University Hospital (Suècia))
Kornhuber, Johannes (Universitätsklinikum Erlangen)
Universitat Autònoma de Barcelona

Date:	2018
Abstract:	In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer's disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e. g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders.
Grants:	Ministerio de Economía y Competitividad AC14/00014
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Ressenya ; recerca ; Versió publicada
Subject:	Alzheimer's disease ; Biomarkers ; Cerebrospinal fluid ; Consensus ; Dementia
Published in:	World Journal of Biological Psychiatry, Vol. 19 Núm. 4 (19 2018) , p. 244-328, ISSN 1814-1412

DOI: 10.1080/15622975.2017.1375556
PMID: 29076399

135 p, 1.9 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles
Articles > Reviews